Trial Profile
A Feasibility Study of Durvalumab (MEDI4736) Alone or in Combination With Oleclumab (MEDI9447) as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Sep 2022
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Oleclumab (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Adverse reactions
- Acronyms BLASST-2
- 08 Sep 2022 Status changed from active, no longer recruiting to completed.
- 14 Mar 2022 Planned primary completion date changed from 31 Jan 2022 to 30 Jun 2022.
- 06 Dec 2021 Planned primary completion date changed from 31 Oct 2021 to 31 Jan 2022.